Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Simulations Plus, Inc.
SLP
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $370.8M
$18.39
▲ +0.22%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.09 - $21.01
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 0.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary AI/ML-powered simulation technology with 28-year development history and regulatory validation
- Integrated software ecosystem covering drug discovery through clinical development phases
- Strong relationships with FDA and global regulatory agencies, enabling faster regulatory approvals
- Specialized expertise in mechanistic modeling and quantitative systems pharmacology with limited direct competitors
- Recurring revenue model through software licensing, consulting services, and contract research
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Steady revenue growth (13% YoY)
Value
Fairly valued vs Healthcare IT & Services peers
Momentum
Hot
+53.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SLP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 8, 2026
APR 9, 2026
Reported EPS of $0.35 vs $0.27 consensus (+29.6% surprise). Revenue of $24.3M vs $21.7M expected (+12.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+29.6%
Next: Apr 8, 2026
Revenue trend · last 8Q
—
—
—
+23%
+10%
-6%
-3%
+8%
Q3 24
Q4 24
Q1 24
Q2 25
Q3 25
Q4 25
Q1 25
Q2 26
$18.5M
$18.7M
$18.9M
$22.4M
$20.4M
$17.5M
$18.4M
$24.3M
Margins · last 8Q
Gross
66.5%
Operating
23.2%
Profit
18.7%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Jun 18, 2026